NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05177211 2025-12-15
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT01420770 2025-03-05
Phase 2 Study of SAR302503 in Patients With Myelofibrosis
Bristol-Myers Squibb
Phase 2 Completed
NCT01420783 2025-03-05
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
Bristol-Myers Squibb
Phase 2 Completed
NCT01437787 2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3 Completed
NCT01523171 2025-03-05
JAKARTA2
Bristol-Myers Squibb
Phase 2 Completed
NCT04955938 2024-07-31
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Phase 1 Withdrawn